Paper Details

  1. Home
  2. Paper Details

Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments.

Author: BhulaniNizar, RowanPaul J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Chronic hepatitis C virus (HCV) is a global concern. This review discusses the impact of the 2014 Food and Drug Administration approvals of two direct-acting antiviral (DAA) regimens on the need for psychosocial assessment and monitoring in HCV patients. The review concludes that the new DAA regimens, which are more effective and have fewer side effects, have reduced the need for psychosocial assessment and monitoring, although some clinical issues will still require attention.
Paper Details　
Original Abstract of the Article :
Chronic hepatitis C virus (HCV) is a global concern. With the 2014 Food and Drug Administration approvals of two direct-acting antiviral (DAA) regimens, ledipasvir/sofosbuvir regimen and the ombitasvir/paritaprevir/ritonavir and dasabuvir regimen, we may now be in the era of all-pill regimens for HC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561775/

データ提供：米国国立医学図書館（NLM）

Psychosocial Assessment in the Era of New HCV Treatments

The study focuses on the evolving landscape of hepatitis C virus (HCV) treatment, specifically examining the role of psychosocial assessment and monitoring in the wake of new direct-acting antiviral (DAA) regimens. The authors discuss how the introduction of DAAs, which offer improved efficacy and reduced side effects compared to traditional interferon-alpha-based treatments, has significantly impacted the need for extensive psychosocial assessments. While the shorter treatment timelines and easier regimens have reduced the burden of psychosocial considerations, certain aspects like psychiatric comorbidity and drug-drug interactions still require clinical attention. The authors conclude that the era of extensive psychosocial assessment and monitoring may be coming to an end, but a moderate level of clinical attention is still necessary to ensure optimal treatment outcomes.

The Shifting Landscape of HCV Treatment

The study suggests that the advent of direct-acting antiviral (DAA) regimens has significantly simplified the treatment landscape for hepatitis C virus (HCV) infection. The improved efficacy and reduced side effects of DAAs have lessened the need for extensive psychosocial assessment and monitoring. This shift is a positive development, potentially allowing for wider access to effective treatments and improved patient outcomes.

A Camel's Perspective on HCV Treatment

The introduction of DAA regimens for HCV treatment is like discovering a hidden spring in the desert - a source of relief and hope. The reduced need for psychosocial assessment and monitoring is a significant step forward, but we must remain vigilant about potential challenges. It's like navigating a desert with a compass - we need to be aware of the changing sands and adapt our approach accordingly.

Dr.Camel's Conclusion

New direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection have simplified treatment, reducing the need for extensive psychosocial assessment. However, some clinical attention is still required.
Date :
  1. Date Completed 2015-09-18
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26380046

DOI: Digital Object Identifier

PMC4561775

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.